A prognosis and impact factor analysis of DC-CIK cell therapy for patients with hepatocellular carcinoma undergoing postoperative TACE

被引:49
作者
Zhang, Jian [1 ]
Li, Huizhong [1 ]
Gao, Dazhi [1 ,4 ]
Zhang, Baofu [1 ]
Zheng, Maojin [2 ]
Lun, Mingyin [1 ]
Wei, Mengxue [1 ]
Duan, Rui [1 ]
Guo, Maomao [1 ]
Hua, Jiajun [1 ]
Liu, Qian [1 ]
Bai, Jin [1 ]
Liu, Hui [2 ,3 ]
Zheng, Junnian [1 ,3 ]
Yao, Hong [1 ]
机构
[1] Xuzhou Med Univ, Inst Canc, Jiangsu Ctr Collaborat & Innovat Canc Biotherapy, Xuzhou, Jiangsu, Peoples R China
[2] Xuzhou Med Univ, Sch Biomed Sci, Dept Pathol, Xuzhou, Jiangsu, Peoples R China
[3] Xuzhou Med Univ, Affiliated Hosp, Xuzhou, Jiangsu, Peoples R China
[4] Nanjing Gen Hosp, Dept Radiol, Nanjing Mil Command PLA, Nanjing, Jiangsu, Peoples R China
基金
中国国家自然科学基金;
关键词
Hepatocellular carcinoma; Cytokine-induced killer cell immunotherapy; PD-L1; Tissue microarray; Immunohistochemistry; Transcatheter arterial chemoembolization; TUMOR-INFILTRATING LYMPHOCYTES; TRANSARTERIAL CHEMOEMBOLIZATION; CANCER-IMMUNOTHERAPY; PD-L1; EXPRESSION; HCC; PATHOGENESIS; METAANALYSIS; RECURRENCE; ACTIVATION; EVASION;
D O I
10.1080/15384047.2018.1433501
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Dendritic cell-cytokine-induced killer (DC-CIK) cell therapy has been experimentally implemented for enhancing anti-tumoral immunity in patients with hepatocellular carcinoma (HCC) undergoing postoperative transcatheter arterial chemoembolization (POTACE). We performed a retrospective study to evaluate the clinical efficacies of DC-CIK cell therapy and its correlations with several immune factors of the primary tumors. The overall survival time of HCC patients with HBV infection in the study group (POTACE plus DC-CIK cell therapy) was significantly longer than that of the control group (POTACE alone). The expression level of PD-L1 but not the tumor-infiltrated CD8 and CD4 T cells in the tumor tissues showed significant negative correlations with relapse-free survival (RFS) and overall survival (OS), which was also an independent prognostic factor for the five-years' suvival of patients with HCC receiving POTACE treatment. Furthermore, our study validated that PD-L1 expression was significantly inversely correlated with the survival time of HCC patients receiving POTACE plus DC-CIK cell therapy treatment. More importantly, DC-CIK cell therapy provided the best clinical benefits to HCC patients with the low PD-L1 expression receiving POTACE, which indicate that PD-L1 expression level can serve as a pivotal predictor for the therapeutic efficacy of DC-CIK cell therapy for HCC patients receiving POTACE treatment.
引用
收藏
页码:475 / 483
页数:9
相关论文
共 36 条
  • [1] Intratumoral expression of programmed death ligand 1 (PD-L1) in patients with clear cell renal cell carcinoma (ccRCC)
    Abbas, M.
    Steffens, S.
    Bellut, M.
    Eggers, H.
    Grosshennig, A.
    Becker, J. U.
    Wegener, G.
    Schrader, A. J.
    Gruenwald, V.
    Ivanyi, P.
    [J]. MEDICAL ONCOLOGY, 2016, 33 (07)
  • [2] BRG1 expression is increased in human glioma and controls glioma cell proliferation, migration and invasion in vitro
    Bai, Jin
    Mei, Peng-Jin
    Liu, Hui
    Li, Chen
    Li, Wang
    Wu, Yong-Ping
    Yu, Zheng-Quan
    Zheng, Jun-Nian
    [J]. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2012, 138 (06) : 991 - 998
  • [3] Activation of the PD-1/PD-L1 immune checkpoint confers tumor cell chemoresistance associated with increased metastasis
    Black, Madison
    Barsoum, Ivraym B.
    Truesdell, Peter
    Cotechini, Tiziana
    Macdonald-Goodfellow, Shannyn K.
    Petroff, Margaret
    Siemens, D. Robert
    Koti, Madhuri
    Craig, Andrew W. B.
    Graham, Charles H.
    [J]. ONCOTARGET, 2016, 7 (09) : 10557 - 10567
  • [4] PD-L1 expression as a predictive biomarker for cytokine-induced killer cell immunotherapy in patients with hepatocellular carcinoma
    Chen, Chang-Long
    Pan, Qiu-Zhong
    Zhao, Jing-Jing
    Wang, Ying
    Li, Yong-Qiang
    Wang, Qi-Jing
    Pan, Ke
    Weng, De-Sheng
    Jiang, Shan-Shan
    Tang, Yan
    Zhang, Xiao-Fei
    Zhang, Hong-Xia
    Zhou, Zi-Qi
    Zeng, Yi-Xin
    Xia, Jian-Chuan
    [J]. ONCOIMMUNOLOGY, 2016, 5 (07):
  • [5] Cellular and molecular mechanisms of liver tolerance
    Crispe, Ian N.
    Giannandrea, Matthew
    Klein, Ingo
    John, Beena
    Sampson, Bradford
    Wuensch, Sherry
    [J]. IMMUNOLOGICAL REVIEWS, 2006, 213 : 101 - 118
  • [6] Implication of combined PD-L1/PD-1 blockade with cytokine-induced killer cells as a synergistic immunotherapy for gastrointestinal cancer
    Dai, Congqi
    Lin, Fengjuan
    Geng, Ruixuan
    Ge, Xiaoxiao
    Tang, Wenbo
    Chang, Jinjia
    Wu, Zheng
    Liu, Xinyang
    Lin, Ying
    Zhang, Zhe
    Li, Jin
    [J]. ONCOTARGET, 2016, 7 (09) : 10332 - 10344
  • [7] Is Adjuvant Cellular Immunotherapy Essential after TACE-Predominant Minimally-Invasive Treatment for Hepatocellular Carcinoma? A Systematic Meta-Analysis of Studies Including 1774 Patients
    Ding, Min
    Wang, Ying
    Chi, Jiachang
    Wang, Tao
    Tang, Xiaoyin
    Cui, Dan
    Qian, Qijun
    Zhai, Bo
    [J]. PLOS ONE, 2016, 11 (12):
  • [8] Dong HD, 2002, NAT MED, V8, P793, DOI 10.1038/nm730
  • [9] CURRENT CONCEPTS Hepatocellular Carcinoma
    El-Serag, Hashem B.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2011, 365 (12) : 1118 - 1127
  • [10] PD-L1 Limits the Mucosal CD8+ T Cell Response to Chlamydia trachomatis
    Fankhauser, Sarah C.
    Starnbach, Michael N.
    [J]. JOURNAL OF IMMUNOLOGY, 2014, 192 (03) : 1079 - 1090